News
LH
207.94
-0.01%
-0.03
Madison Mid Cap Fund Q1 2024 Investment Strategy Letter
The Madison Mid Cap Fund (Class Y) increased 9.63% in the first quarter of 2024, compared to the 8.60% increase in the Russell Midcap Index. The top five contributors for the quarter were Arch Capital Group, PACCAR, Arista Networks, and Brown & Brown. The bottom five detractors were Liberty Broadband, Dollar Tree, and Glacier Bancorp.
Seeking Alpha · 22h ago
Laboratory Corporation of America Holdings <LH.N> expected to post earnings of $3.48 a share - Earnings Preview
Laboratory Corporation of America Holdings expected to post earnings of $3.48 a share. The company is expected to show a fall in quarterly revenue when it reports results on April 25 for the period ending March 31 2024. Analysts expect the company to report a 17.5% decrease in revenue.
Reuters · 1d ago
Merit Medical (MMSI) Earnings Expected to Grow: Should You Buy?
NASDAQ · 1d ago
Goldman’s buybacks basket: Buyback growth will be 13% in 2024
Goldman’s buybacks basket: Buyback growth will be 13% in 2024. Goldman Sachs analysts rebalanced their “buybacks basket” as 2024 buyback growth is forecasted to be 13%. S&P 500 (SP500) cash spending grew by 4% to $3.4T last year.
Seeking Alpha · 2d ago
Weekly Report: what happened at LH last week (0415-0419)?
Weekly Report · 2d ago
Mayar Capital Q1 2024 Letter To Partners
Seeking Alpha · 5d ago
5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings
NASDAQ · 5d ago
Labcorp (LH) Expected to Beat Earnings Estimates: Should You Buy? (Revised)
NASDAQ · 5d ago
Laboratory Corp. of America on Track for Longest Losing Streak Since December 2018 -- Data Talk
Laboratory Corporation of America Holdings (LH) is currently at $198.93, down $1.04 or 0.52%. Down 10 of the past 11 days; currently down nine consecutive days. Down 26.3% from its all-time closing high of $269.93.
Dow Jones · 6d ago
Why Labcorp (LH) Could Beat Earnings Estimates Again
NASDAQ · 6d ago
Labcorp (LH) to Report Q1 Earnings: What's in the Cards?
NASDAQ · 04/16 12:42
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Laboratory (LH) and Longboard Pharmaceuticals (LBPH)
TipRanks · 04/16 10:00
Laboratory Corporation of America Holdings Enters Oversold Territory (LH)
NASDAQ · 04/15 20:46
Laboratory Corporation of America Holdings (NYSE:LH) Is Due To Pay A Dividend Of $0.72
Laboratory Corporation of America Holdings will pay a dividend of $0.72 per share on the 12th of June. The company has a 1.4% dividend yield and is comfortably earning enough to cover its payments. The last annual payment of $2.88 was flat on the previous year. We don't see much growth potential for the company.
Simply Wall St · 04/15 18:50
LABCORP: AVAILABILITY OF TEST FOR GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP)
Reuters · 04/15 11:02
Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw
Innovative GFAP blood biomarker test expands Labcorp's portfolio of tests for diseases including Alzheimer's disease, multiple sclerosis, glioblastoma and brain injuries. The new GFAP test is the nation's first test for glial fibrillary acidic protein. GFAP is a critical blood-based biomarker for the early detection of neurodegenerative diseases and neurological injuries.
PR Newswire · 04/15 11:00
Weekly Report: what happened at LH last week (0408-0412)?
Weekly Report · 04/15 09:16
Labcorp's (LH) At-Home Mpox Testing Kit Gets the FDA's EUA Nod
NASDAQ · 04/12 13:10
Myriad Genetics (MYGN) Announces Favorable Research Results
NASDAQ · 04/11 14:00
Laboratory Corp Announces Upcoming Cash Dividend Payout
TipRanks · 04/11 12:52
More
Webull provides a variety of real-time LH stock news. You can receive the latest news about Laboratory Corp Amer Hldgs through multiple platforms. This information may help you make smarter investment decisions.
About LH
Laboratory Corporation of America Holdings provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.